

Adolor, EpiCept join up on post-surgical patch

where he was responsible for the production of vaccines, diagnostic blood typing and screening reagents, and the **Liposome Co.**, where he was responsible for the technology transfer and the production of sterile products.

More for FemmePharma

FemmePharma Inc., a Wayne-based pharmaceutical company specializing in developing new drugs for women's health ailments, recently completed a new round of financing.

The amount of the private stock placement was not disclosed.

Wynnefield Capital Advisors, one of FemmePharma's existing investors, provided the capital that the company said it will use to continue clinical development of its experimental urinary incontinence product and to continue its pharmaceutical development for its fibrocystic breast disease product.

The financing will also be used for working capital for the organization.

"FemmePharma is pleased by Wynnefield's continued support," said **Gerianne Tringali-DiPiano**, the company's president and CEO. "This recent investment will allow us to accelerate the development of products in our pipeline, ultimately to product launch."

Andrea McFadden, a partner at Wynnefield Capital Advisors and a board member of FemmePharma, said, "We continue to be excited about being a part of FemmePharma's team. Women's health care is an emerging market, and FemmePharma has been especially intelligent in taking a product design approach that is specifically geared to a woman's physiology. We think they will prove to be uniquely positioned to develop this underserved market."

FemmePharma was founded by Tringali-DiPiano in 1996 to target the estimated \$35 billion women's health-care pharmaceutical market. The company is concluding phase-II clinical trials for its first drug, a new treatment for endometriosis (a condition where endometrium or the lining of the uterus is found in locations outside the uterus).



Biotech

John
George